MB 101 - Must bio
Alternative Names: MB-101 - MustbioLatest Information Update: 30 Jun 2023
At a glance
- Originator Must Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Jun 2023 MB 101 - Mustbio is available for licensing as of 09 Jun 2023. http://mustbio.com/sub/sub04.php
- 14 Apr 2023 Preclinical trials in Cancer in South Korea (Parenteral) prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from preclinical trial in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)